Heart failure is a global health problem and a leading cause of hospitalisation and death – and patients are currently underserved. AnaCardio is a Swedish clinical stage biotech company developing novel drugs to treat heart failure. The company was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. 

www.anacardio.com